A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patients with sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmopoulos, Andrew, Bhatt, Deepak L., Meglis, Gus, Verma, Raj, Pan, Yi, Quan, Adrian, Teoh, Hwee, Verma, Maya, Jiao, Lixia, Wang, Robert, Juliano, Rebecca A., Kajil, Mahesh, Kosiborod, Mikhail N., Bari, Basel, Berih, Abdullahi A., Aguilar, Mallory, Escano, Antonnette, Leung, Andrew, Coelho, Idelta, Hibino, Makoto, Díaz, Rafael, Mason, R. Preston, Steg, Ph. Gabriel, Simon, Tabassome, Go, Alan S., Ambrosy, Andrew P., Choi, Richard, Kushner, Arthur M., Leiter, Lawrence A., Al-Omran, Mohammed, Verma, Subodh, Mazer, C. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388138/
https://www.ncbi.nlm.nih.gov/pubmed/34462732
http://dx.doi.org/10.1016/j.isci.2021.103040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388138/
https://www.ncbi.nlm.nih.gov/pubmed/34462732
http://dx.doi.org/10.1016/j.isci.2021.103040

Ejemplares similares